News
InvestorsHub on MSN16m
AstraZeneca’s anselamimab misses primary endpoint in key trial, shares fallAstraZeneca’s (NYSE:AZN) rare disease division, Alexion, announced that its experimental treatment anselamimab did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback